Rituximab: modes of action, remaining dispute and future perspective

Hypogammaglobulinaemia after rituximab treatment--incidence and outcomes

(2014) M. Makatsori et al.   QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab

(2013) Zi-Zhen Xu et al.   ANNALS OF HEMATOLOGY

Cleavage of the interchain disulfide bonds in rituximab increases its affinity for FcγRIIIA

(2013) Mami Suzuki et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Obinutuzumab: First Global Approval

(2013) Fiona Cameron et al.   DRUGS

Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study

(2013) Gilles A. Salles et al.   JOURNAL OF CLINICAL ONCOLOGY

Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity

(2013) S Hörl et al.   LEUKEMIA

Hydroxyurea Potentiates the Caspase-Independent Killing of B-Cell Lines by Rituximab and GA101

(2013) Ian Daniels et al.   ONCOLOGY RESEARCH

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Rituximab resistance

(2011) Andrew R. Rezvani et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

CD40 stimulation sensitizes CLL cells to rituximab-induced cell death

(2011) M Jak et al.   LEUKEMIA

Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101

(2011) S. Dalle et al.   MOLECULAR CANCER THERAPEUTICS

Rituximab in Indolent Lymphomas

(2010) Tarek Sousou et al.   SEMINARS IN HEMATOLOGY

The involvement of mitochondria and the caspase-9 activation pathway in rituximab-induced apoptosis in FL cells

(2009) Jonna Eeva et al.   APOPTOSIS

Involvement of macroautophagy in the caspase-independent killing of Burkitt lymphoma cell lines by rituximab

(2009) Julie Turzanski et al.   BRITISH JOURNAL OF HAEMATOLOGY

Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions

(2009) M. I. Vega et al.   CLINICAL CANCER RESEARCH

Depletion of peripheral blood B cells with Rituximab and phenotype characterization of the recovering population in a patient with follicular lymphoma

(2009) Abdulmunem M. Abulayha et al.   LEUKEMIA RESEARCH

Is complement good or bad for cancer patients? A new perspective on an old dilemma

(2009) Maciej M. Markiewski et al.   TRENDS IN IMMUNOLOGY

Novel roles for ceramides, calpains and caspases in kidney proximal tubule cell apoptosis: Lessons from in vitro cadmium toxicity studies

(2008) Wing-Kee Lee et al.   BIOCHEMICAL PHARMACOLOGY

A requirement for calcium in the caspase-independent killing of Burkitt lymphoma cell lines by Rituximab

(2008) Ian Daniels et al.   BRITISH JOURNAL OF HAEMATOLOGY

Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16

(2008) Christophe de Romeuf et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bcl-2 inhibitors: small molecules with a big impact on cancer therapy

(2008) M Vogler et al.   CELL DEATH AND DIFFERENTIATION

A review of the current use of rituximab in autoimmune diseases

(2008) Hakan M. Gürcan et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II Study

(2008) Guillaume Cartron et al.   JOURNAL OF CLINICAL ONCOLOGY

The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy

(2008) X. Zhou et al.   ONCOLOGIST